FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380729973> ?p ?o ?g. }

• W4380729973 endingPage "e2318487" @default.
• W4380729973 startingPage "e2318487" @default.
• W4380729973 abstract "Prior authorization (PA) requirements for buprenorphine are associated with lower provision of the medication for the treatment of opioid use disorder (OUD). While Medicare plans have eliminated PA requirements for buprenorphine, many Medicaid plans continue to require them.To describe and classify buprenorphine coverage requirements based on thematic analysis of state Medicaid PA forms.This qualitative study used a thematic analysis of 50 states' Medicaid PA forms for buprenorphine between November 2020 and March 2021. Forms were obtained from the jurisdiction's Medicaid websites and assessed for features suggesting barriers to buprenorphine access. A coding tool was developed based on a review of a sample of forms, including fields for behavioral health treatment recommendations or mandates, drug screening requirements, and dosage limitations.Outcomes included PA requirements for different buprenorphine formulations. Additionally, PA forms were evaluated for various criteria such as behavioral health, drug screenings, dose-related recommendations or mandates or patient education.Among the total of 50 US states in the analysis, most states' Medicaid plans required PA for at least 1 formulation of buprenorphine. However, the majority did not require a PA for buprenorphine-naloxone. Four key themes of coverage requirements were identified: restrictive surveillance (eg, requirements for urine drug screenings, random drug screenings, pill counts), behavioral health treatment recommendations or mandates (eg, mandatory counseling or 12-step meeting attendance), interfering with or restricting medical decision-making (eg, maximum daily dosages of 16 mg, requiring additional steps for dosages higher than 16 mg), and patient education (eg, information about adverse effects and interactions with other medications). Eleven states (22%) required urine drug screenings, 6 states (12%) required random urine drug screenings, and 4 states (8%) required pill counts. Fourteen states' forms (28%) recommended therapy, and 7 (14%) required therapy, counseling, or participation in group sessions. Eighteen states (36%) specified dosage maximums; among them, 11 (22%) required additional steps for a daily dosage higher than 16 mg.In this qualitative study of state Medicaid PA requirements for buprenorphine, themes were identified that included patient surveillance with drug screenings and pill counts, behavioral health treatment recommendations or mandates, patient education, and dosing guidance. These results suggest that state Medicaid plans' buprenorphine PA requirements for OUD are in conflict with existing evidence and may negatively affect states' efforts to address the opioid overdose crisis." @default.
• W4380729973 created "2023-06-16" @default.
• W4380729973 creator A5009280278 @default.
• W4380729973 creator A5043085457 @default.
• W4380729973 creator A5044084276 @default.
• W4380729973 creator A5053869549 @default.
• W4380729973 creator A5063784430 @default.
• W4380729973 creator A5065323473 @default.
• W4380729973 date "2023-06-15" @default.
• W4380729973 modified "2023-10-16" @default.
• W4380729973 title "Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements" @default.
• W4380729973 cites W1798755738 @default.
• W4380729973 cites W1824941658 @default.
• W4380729973 cites W2019565950 @default.
• W4380729973 cites W2073606903 @default.
• W4380729973 cites W2103355133 @default.
• W4380729973 cites W2113525428 @default.
• W4380729973 cites W2123935188 @default.
• W4380729973 cites W2130758264 @default.
• W4380729973 cites W2167911929 @default.
• W4380729973 cites W2224469352 @default.
• W4380729973 cites W2331393505 @default.
• W4380729973 cites W2510073630 @default.
• W4380729973 cites W2782941988 @default.
• W4380729973 cites W2912937853 @default.
• W4380729973 cites W2964194900 @default.
• W4380729973 cites W3010658253 @default.
• W4380729973 cites W3016822260 @default.
• W4380729973 cites W3017055826 @default.
• W4380729973 cites W3030409123 @default.
• W4380729973 cites W3086036271 @default.
• W4380729973 cites W3105724865 @default.
• W4380729973 cites W3109318125 @default.
• W4380729973 cites W3124976223 @default.
• W4380729973 cites W3156324838 @default.
• W4380729973 cites W3159547645 @default.
• W4380729973 cites W4249774886 @default.
• W4380729973 cites W4251366796 @default.
• W4380729973 cites W4289262330 @default.
• W4380729973 doi "https://doi.org/10.1001/jamanetworkopen.2023.18487" @default.
• W4380729973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37318805" @default.
• W4380729973 hasPublicationYear "2023" @default.
• W4380729973 type Work @default.
• W4380729973 citedByCount "0" @default.
• W4380729973 crossrefType "journal-article" @default.
• W4380729973 hasAuthorship W4380729973A5009280278 @default.
• W4380729973 hasAuthorship W4380729973A5043085457 @default.
• W4380729973 hasAuthorship W4380729973A5044084276 @default.
• W4380729973 hasAuthorship W4380729973A5053869549 @default.
• W4380729973 hasAuthorship W4380729973A5063784430 @default.
• W4380729973 hasAuthorship W4380729973A5065323473 @default.
• W4380729973 hasBestOaLocation W43807299731 @default.
• W4380729973 hasConcept C118552586 @default.
• W4380729973 hasConcept C126322002 @default.
• W4380729973 hasConcept C144024400 @default.
• W4380729973 hasConcept C159110408 @default.
• W4380729973 hasConcept C160735492 @default.
• W4380729973 hasConcept C162324750 @default.
• W4380729973 hasConcept C170493617 @default.
• W4380729973 hasConcept C190248442 @default.
• W4380729973 hasConcept C2776534028 @default.
• W4380729973 hasConcept C2778767360 @default.
• W4380729973 hasConcept C2778949969 @default.
• W4380729973 hasConcept C2779418921 @default.
• W4380729973 hasConcept C2779598192 @default.
• W4380729973 hasConcept C2781063702 @default.
• W4380729973 hasConcept C36289849 @default.
• W4380729973 hasConcept C50522688 @default.
• W4380729973 hasConcept C512399662 @default.
• W4380729973 hasConcept C71924100 @default.
• W4380729973 hasConcept C74196892 @default.
• W4380729973 hasConceptScore W4380729973C118552586 @default.
• W4380729973 hasConceptScore W4380729973C126322002 @default.
• W4380729973 hasConceptScore W4380729973C144024400 @default.
• W4380729973 hasConceptScore W4380729973C159110408 @default.
• W4380729973 hasConceptScore W4380729973C160735492 @default.
• W4380729973 hasConceptScore W4380729973C162324750 @default.
• W4380729973 hasConceptScore W4380729973C170493617 @default.
• W4380729973 hasConceptScore W4380729973C190248442 @default.
• W4380729973 hasConceptScore W4380729973C2776534028 @default.
• W4380729973 hasConceptScore W4380729973C2778767360 @default.
• W4380729973 hasConceptScore W4380729973C2778949969 @default.
• W4380729973 hasConceptScore W4380729973C2779418921 @default.
• W4380729973 hasConceptScore W4380729973C2779598192 @default.
• W4380729973 hasConceptScore W4380729973C2781063702 @default.
• W4380729973 hasConceptScore W4380729973C36289849 @default.
• W4380729973 hasConceptScore W4380729973C50522688 @default.
• W4380729973 hasConceptScore W4380729973C512399662 @default.
• W4380729973 hasConceptScore W4380729973C71924100 @default.
• W4380729973 hasConceptScore W4380729973C74196892 @default.
• W4380729973 hasIssue "6" @default.
• W4380729973 hasLocation W43807299731 @default.
• W4380729973 hasLocation W43807299732 @default.
• W4380729973 hasLocation W43807299733 @default.
• W4380729973 hasOpenAccess W4380729973 @default.
• W4380729973 hasPrimaryLocation W43807299731 @default.
• W4380729973 hasRelatedWork W1979517098 @default.
• W4380729973 hasRelatedWork W1991355918 @default.

• next